Nirsevimab implementation in Catalonia, Spain, reduced emergency department visits and hospital admissions for bronchiolitis ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis. This is the ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May ...

Universal immunisation with nirsevimab significantly reduces hospitalizations and paediatric intensive care admissions for ...

RSV leads to over 100,000 infant deaths annually, but WHO’s latest guidance recommends maternal vaccines and monoclonal ...

Maternal vaccination and, to a lesser extent, nirsevimab appear to significantly reduce RSV-related hospitalizations in infants.

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the ...

In response to the global burden of severe RSV disease among infants, WHO recommends that all countries introduce either the ...

The World Health Organization (WHO) has published its first ever position paper on immunization against respiratory syncytial ...

A statewide immunization program for infants against respiratory syncytial virus (RSV), which began in 2024, has already ...